A cancer diagnosis changes everything. It affects your private life and your professional life, a huge challenge for any person. It can also impact every company, as employees are the most valuable assets a company has.
With our Corporate Oncology Program for Employees (COPE), companies have the opportunity to give impacted employees straightforward access to comprehensive tumor diagnostics and evaluation as part of a health management program. This can help cancer patients receive better treatment.
Together against cancer – with COPE
Molecular Health, a company of dievini Hopp Biotech holding GmbH & Co. KG, has developed a groundbreaking software solution that gives physicians personalized treatment options for individual patients. This solution – MH Guide – is the first software of its kind registered as an in-vitro diagnostic (IVD) medical device in Europe, according to the EU regulation 2017/746 (IVDR). MH Guide analyzes and interprets the patient’s genetic tumor profile. Based on these results, the attending physician can, if necessary, identify suitable drugs or clinical trials for individualized treatment.
PhD Friedrich von Bohlen und Halbach
Chief Executive Officer
“With our COPE program, we offer other companies access to our patient-centered solutions, so that they can support their workforce in the best possible way.”
“Our employees are the heart of our company. If anyone gets cancer, we want to ensure that they receive the best possible diagnostics and the most suitable therapy. COPE lets us do this.”
PhD Natalie Lotzmann
Global Head of Health & Well-Being,
Chief Medical Officer at SAP SE, Walldorf
All patients can be sure that none of their personal data will be passed on to Molecular Health by their employer or physician.
Only the attending physician and the molecular pathologist have access to patient data that allow conclusions to be drawn about identity. Molecular Health works exclusively with pseudonymized data.
© 2021 Molecular Health GmbH
© 2020 Molecular Health GmbH